Repros Therapeutics Inc (NASDAQ:RPRX) reported that vaginal administration of Proellex ® at doses of both 6 and 12 mg achieved significant reduction in excessive …
Repros Therapeutics Inc (NASDAQ:RPRX) announced that it has received a Complete Response Letter from the U.S.
Repros Therapeutics Inc (NASDAQ:RPRX) announced financial results for the third quarter ended September 30, 2015. Financial Results Net loss for the three month …
Analysts are weighing in on the controversial drug giant Valeant Pharmaceuticals Intl Inc (NYSE:VRX) and drug company Repros Therapeutics Inc (NASDAQ:RPRX), as shares …
In a research report published Thursday, Piper Jaffray analyst Joshua Schimmer reiterated a Neutral rating on shares of Repros Therapeutics Inc (NASDAQ:RPRX), while reducing …
Earlier today, Brean Capital’s healthcare analyst Jonathan Aschoff weighed in with research reports on the DNA product development company Inovio Pharmaceuticals Inc (NASDAQ:INO), Biopharmaceutical company Repros Therapeutics Inc (NASDAQ:RPRX), …
In a research report released today, Brean Capital analyst Jonathan Aschoff reiterated a Buy rating on shares of Repros Therapeutics Inc (NASDAQ:RPRX) with a …
Repros Therapeutics Inc (NASDAQ:RPRX) announced financial results for the second quarter ended June 30, 2015. Financial Results Net loss for the three month …
Repros Therapeutics Inc (NASDAQ:RPRX) announced that the Division of Bone, Reproductive and Urologic Products of the U.S.
Equity analysts have recently weighed in with favorable reports on Repros Therapeutics Inc (NASDAQ:RPRX), as the company’s Androxal AdCom meeting and PDUFA preparations are in high …
